---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-048552"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:11:04.282686+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune raises ~$211M in public offering to fund MASH Phase 3 trial

## Summary
- Offered 64.25M common shares at $3.00/share and pre-funded warrants for up to 10.75M shares.
- Net proceeds of ~$211.2M after underwriting discounts and expenses; offering closed April 24, 2026.
- Proceeds to fund pemvidutide Phase 3 MASH trial and pre-commercial activities.
- Common stock warrants exercisable at $3.00/share for 5 years or 45 days after Phase 3 data announcement.
- Warrants not listed on Nasdaq; beneficial ownership limits of 4.99% or 9.99% apply.

## SEC filing metadata
- accession: 0001104659-26-048552
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/tm2612493d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-048552
- JSON: https://secwatch.observer/filing/0001104659-26-048552.json
- Plain text: https://secwatch.observer/filing/0001104659-26-048552.txt

## Source-grounded claims
- claim_id: a0533c74eb6df3b88485d25967a150807282e774
  claim: Altimmune, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $211.2 million (effective 2026-04-22).
  evidence_excerpt: On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock warrants to purchase shares of Common Stock (the “ Common Stock Warrants ”), to the Underwriters at a public offering price of $3.00 per share and (ii) in lieu of Common Stock to certain investors that so choose, pre-funded warrants (the “ Pre-Funded Warrants ” and together with the Common Stock Warrants, the “ Warrants ”) to purchase up to 10,750,000 shares of Common Stock to the Underwriters at a public offering price of $2.999 per Pre-Funded Warrant (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/0001104659-26-048552-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.